+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Interleukin 13"

Interleukin 13 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin 13 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Interleukin-13 (IL-13) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-13 (IL-13) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Atopic Dermatitis Drugs - Global Strategic Business Report - Product Thumbnail Image

Atopic Dermatitis Drugs - Global Strategic Business Report

  • Report
  • April 2025
  • 179 Pages
  • Global
From
Urticaria- Pipeline Insight, 2025 - Product Thumbnail Image

Urticaria- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Chronic Spontaneous Urticaria- Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Spontaneous Urticaria- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Interleukin 4 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin 4 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Moderate To Severe Atopic Dermatitis - Pipeline Insight, 2025 - Product Thumbnail Image

Moderate To Severe Atopic Dermatitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
From
  • 10 Results (Page 1 of 1)
Loading Indicator

Interleukin 13 (IL-13) is a cytokine that plays a role in the regulation of the immune system. It is involved in the development of immune disorders such as asthma, allergies, and inflammatory bowel disease. IL-13 is a key target for drug development in the immune disorders market, as it has been shown to reduce inflammation and improve symptoms. IL-13 is a promising target for drug development due to its ability to modulate the immune system. It has been shown to reduce inflammation and improve symptoms in a variety of immune disorders. Additionally, IL-13 has been shown to be effective in combination with other drugs, making it a viable option for combination therapies. Several companies are developing drugs targeting IL-13 for the treatment of immune disorders. These include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more